(129 days)
Not Found
No
The description focuses on mechanical components and operation, with no mention of AI, ML, or image processing.
Yes
The device is described as an "atherectomy" system intended to treat atherosclerotic lesions by excising plaque, which directly addresses a medical condition.
No
Explanation: The "Intended Use/Indications for Use" and "Device Description" sections clearly state that the TurboHawk Peripheral Plaque Excision System is designed for "atherectomy" and the "treatment of de novo and restenotic calcified and noncalcified atherosclerotic lesions." This indicates it is a therapeutic device for removing plaque, not a diagnostic device used to identify or measure a medical condition.
No
The device description clearly details physical components like a catheter, cutter assembly, and a battery-driven handheld unit, indicating it is a hardware device.
Based on the provided information, the TurboHawk® Peripheral Plaque Excision System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for "atherectomy of the peripheral vasculature," which is a surgical procedure performed within the body to remove plaque from arteries. IVD devices are used to examine specimens outside the body (in vitro) to provide information for diagnosis, monitoring, or screening.
- Device Description: The description details a mechanical system with a cutting assembly designed to physically remove tissue from within a blood vessel. This is a therapeutic device, not a diagnostic one.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.) or providing diagnostic information based on such analysis. The device's function is purely mechanical removal of plaque.
Therefore, the TurboHawk® Peripheral Plaque Excision System is a therapeutic medical device, not an IVD.
N/A
Intended Use / Indications for Use
The TurboHawk® Peripheral Plaque Excision System is intended for use in atherectomy of the peripheral vasculature. The TurboHawk is indicated for use in conjunction with the SpiderFX® Embolic Protection Device in the treatment of severely calcified lesions. The TurboHawk is NOT intended for use in coronary, carotid, iliac or renal vasculature.
Product codes (comma separated list FDA assigned to the subject device)
MCW
Device Description
The TurboHawk® Peripheral Plaque Excision System (TurboHawk Catheter and ev3 Cutter Driver) is designed for the treatment of de novo and restenotic calcified and noncalcified atherosclerotic lesions located in native peripheral arteries. When used in complex, hard, calcified lesions, the TurboHawk should be paired with the SpiderFX® Embolic Protection Device to mitigate any risk of distal embolization that may be generated by the breakdown of heavily calcified plaque. The TurboHawk Catheter consists of a flexible shaft designed to track over a 0.014" guidewire. At the distal end of the TurboHawk Catheter is a small cutting assembly comprised of a rotating inner cutter contained within a tubular housing. The proximal end of the TurboHawk Catheter contains a connector and cutter positioning lever (thumb switch) designed to fit into the ev3 Cutter Driver. The ev3 Cutter Driver is a handheld, disposable, battery-driven unit which powers the system.
The TurboHawk Peripheral Plaque Excision System has two switches: 1) the ev3 Cutter Driver main power switch and 2) the TurboHawk Catheter thumb switch. The ev3 Cutter Driver main power switch supplies power to the device when turned ON. The TurboHawk Catheter thumb switch activates the drive shaft and engages the cutter when pulled proximally to the ON position. With the cutter engaged, the TurboHawk Catheter is slowly advanced across the lesion, shaving occlusive material from the artery. The excised tissue is captured and stored in the tip of the device. The cutting process is completed by advancing the TurboHawk Catheter thumb switch distally deactivating the drive shaft and disengaging the cutter. The TurboHawk Catheter thumb switch is fully advanced distally to the OFF position in order to pack the excised plaque into the tip. This cutting sequence is repeated as necessary to achieve the desired degree of plaque excision.
The TurboHawk Peripheral Plaque Excision System uses the following materials: stainless steel, polyimide, tecothane, pebax, nylon, delrin, PTFE, tungsten carbide, titanium, platinum/iridium, ABS, PVC, silicone, polypropylene and hydrophilic coating.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
peripheral vasculature
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To demonstrate substantial equivalence of the proposed TurboHawk Peripheral Plaque Excision System to the predicate device, the technological characteristics and performance criteria were evaluated. Using internal Risk Analysis procedures, the following tests were performed:
- Compatibility Tests with Embolic Protection Device
- In Vivo Studies
The following tests were performed using the predicate TurboHawk Peripheral Plaque Excision System. Test results met the specified acceptance criteria and were included in K093301: - Cutter Height
- Cycle and Life
- Carbide Edge Attachment
- Driveshaft Torque Tests
- Tensile tests
- Urge Force
- Trackability
- Spin Percentage
- Embolization
- Cut Mass Per Pass
- Tissue Removal
- Package Integrity
- Sterilization
- Biocompatibility
- Shelf Life
The results from these tests demonstrate that the technological characteristics and performance criteria of the TurboHawk Peripheral Plaque Excision System are comparable to the predicate device and that the TurboHawk Peripheral Plaque Excision System performs in a manner equivalent to the predicate device currently on the market.
Clinical Summary:
DEFINITIVE Cat+ was a prospective, multi-center, non-randomized, single-arm study to evaluate the safety and effectiveness of the SilverHawk/TurboHawk and the SpiderFX embolic protection device for the treatment of moderate to severely calcified peripheral arterial disease in the superficial femoral and/or popliteal arteries. An independent Angiographic Core Laboratory and a Clinical Events Committee (CEC) were employed to ensure unbiased review and classification of events and endpoints. 133 subjects from 17 centers were enrolled. The primary safety and effectiveness endpoints were derived from historical registry data using plaque excision.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
The proportion of subjects event-free (per Angiographic Core Laboratory review and CEC adjudication) after 30 days was assessed. The 30-day freedom from MAE rate was 93.1% (122/131). The primary effectiveness endpoint was successful revascularization of the target vessel (defined as less than or equal to 50% residual diameter stenosis following plaque excision), was assessed by the site as well as adjudicated by the angiographic core laboratory. Per angiographic core laboratory assessment, the primary effectiveness criterion (
§ 870.4875 Intraluminal artery stripper.
(a)
Identification. An intraluminal artery stripper is a device used to perform an endarterectomy (removal of plaque deposits from arterisclerotic arteries.)(b)
Classification. Class II (performance standards).
0
KIII7a3
p. 1 of 4
OCT 2 7 2011
Your endovascular company."
510(k) Summary
TurboHawk® Peripheral Plaque Excision System
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 C.F.R § 807.92.
1. Submitter Information
| Applicant | ev3 Inc.
3033 Campus Drive
Plymouth, MN 55441-2651
Tel: 763-398-7000
Fax: 763-591-3248 |
|-----------------------|----------------------------------------------------------------------------------------------------|
| Contact Person | Brenda Johnson
Principal Regulatory Affairs Specialist |
| Date Prepared | October 7, 2011 |
| 2. Subject Device | |
| Device Trade Name | TurboHawk® Peripheral Plaque Excision System |
| Device Common Name | Catheter, Peripheral, Atherectomy |
| Classification Name | Intraluminal Artery Stripper
21 CFR 870.4875, Product Code MCW |
| Classification Panel | Cardiovascular |
| 3. Predicate Devices | |
| Device Trade Name | TurboHawk® Peripheral Plaque Excision System |
| 510(k) Number | K093301 |
| 510(k) Clearance Date | November 6, 2009 |
4. Device Description
The TurboHawk® Peripheral Plaque Excision System (TurboHawk Catheter and ev3 Cutter Driver) is designed for the treatment of de novo and restenotic calcified and noncalcified atherosclerotic lesions located in native peripheral arteries. When used in complex, hard, calcified lesions, the TurboHawk should be paired with the SpiderFX® Embolic Protection Device to mitigate any risk of distal embolization that may be
1
K111703
p. 2 of 4
TurboHawk® Peripheral Plaque Excision System 510(k) Summary
generated by the breakdown of heavily calcified plaque. The TurboHawk Catheter consists of a flexible shaft designed to track over a 0.014" guidewire. At the distal end of the TurboHawk Catheter is a small cutting assembly comprised of a rotating inner cutter contained within a tubular housing. The proximal end of the TurboHawk Catheter contains a connector and cutter positioning lever (thumb switch) designed to fit into the ev3 Cutter Driver. The ev3 Cutter Driver is a handheld, disposable, battery-driven unit which powers the system.
The TurboHawk Peripheral Plaque Excision System has two switches: 1) the ev3 Cutter Driver main power switch and 2) the TurboHawk Catheter thumb switch. The ev3 Cutter Driver main power switch supplies power to the device when turned ON. The TurboHawk Catheter thumb switch activates the drive shaft and engages the cutter when pulled proximally to the ON position. With the cutter engaged, the TurboHawk Catheter is slowly advanced across the lesion, shaving occlusive material from the artery. The excised tissue is captured and stored in the tip of the device. The cutting process is completed by advancing the TurboHawk Catheter thumb switch distally deactivating the drive shaft and disengaging the cutter. The TurboHawk Catheter thumb switch is fully advanced distally to the OFF position in order to pack the excised plaque into the tip. This cutting sequence is repeated as necessary to achieve the desired degree of plaque excision.
The TurboHawk Peripheral Plaque Excision System uses the following materials: stainless steel, polyimide, tecothane, pebax, nylon, delrin, PTFE, tungsten carbide, titanium, platinum/iridium, ABS, PVC, silicone, polypropylene and hydrophilic coating.
5. Indications for Use
The TurboHawk® Peripheral Plaque Excision System is intended for use in atherectomy of the peripheral vasculature. The TurboHawk is indicated for use in conjunction with the SpiderFX® Embolic Protection Device in the treatment of severely calcified lesions. The TurboHawk is NOT intended for use in the coronary, carotid, iliac, or renal vasculature.
6. Comparison of Technological Characteristics
The proposed TurboHawk Peripheral Plaque Excision System is the identical device as the currently marketed TurboHawk Peripheral Plaque Excision System (K093301). The proposed and predicate devices share the following technological characteristics:
- . Fundamental scientific technology and operating principle
- t Design & Dimensions
- Materials .
- Manufacturing site and methods .
- . Sterilization site, method, parameters, and sterility assurance level
- Packaging .
- Shelf Life ●
2
K111723
P. 3 of 4
TurboHawk® Peripheral Plaque Excision System 510(k) Summary
Additionally, the indications for use, intended use, labeling, and Instructions For Use are similar between the proposed and marketed devices. The difference is including use of an ev3 embolic protection device when used in complex, hard, calcified lesions to mitigate risk of distal embolization that may be generated by the breakdown of heavily calcified plaque. Bench testing, in-vivo testing and clinical testing were performed to demonstrate the proposed use of the device with the embolic protection device met predetermined acceptance criteria.
7. Performance Testing Summary
To demonstrate substantial equivalence of the proposed TurboHawk Peripheral Plaque Excision System to the predicate device, the technological characteristics and performance criteria were evaluated. Using internal Risk Analysis procedures, the following tests were performed:
- Compatibility Tests with Embolic Protection Device .
- In Vivo Studies .
The following tests were performed using the predicate TurboHawk Peripheral Plaque Excision System. Test results met the specified acceptance criteria and were included in K093301:
- Cutter Height .
- Cycle and Life ●
- Carbide Edge Attachment
- Driveshaft Torque Tests
- . Tensile tests
- Urge Force ●
- Trackability
- Spin Percentage
- Embolization
- Cut Mass Per Pass
- Tissue Removal
- Package Integrity
- Sterilization
- Biocompatibility
- Shelf Life
The results from these tests demonstrate that the technological characteristics and performance criteria of the TurboHawk Peripheral Plaque Excision System are comparable to the predicate device and that the TurboHawk Peripheral Plaque Excision System performs in a manner equivalent to the predicate device currently on the market.
3
TurboHawk® Peripheral Plaque Excision System 510(k) Summary
8. Clinical Summary
DEFINITIVE Cat+ was a prospective, multi-center, non-randomized, single-arm study to evaluate the safety and effectiveness of the SilverHawk/TurboHawk and the SpiderFX embolic protection device for the treatment of moderate to severely calcified peripheral arterial disease in the superficial femoral and/or popliteal arteries. An independent Angiographic Core Laboratory and a Clinical Events Committee (CEC) were employed to ensure unbiased review and classification of events and endpoints. 133 subjects from 17 centers were enrolled. The primary safety and effectiveness endpoints were derived from historical registry data using plaque excision.
The proportion of subjects event-free (per Angiographic Core Laboratory review and CEC adjudication) after 30 days was assessed. The 30-day freedom from MAE rate was 93.1% (122/131). The primary effectiveness endpoint was successful revascularization of the target vessel (defined as less than or equal to 50% residual diameter stenosis following plaque excision), was assessed by the site as well as adjudicated by the angiographic core laboratory. Per angiographic core laboratory assessment, the primary effectiveness criterion (≤ 50% residual diameter stenosis) was achieved in 92.0% (150/163) of lesions. Per site assessment, the primary endpoint success criterion was achieved in 97.0% (162/167) of lesions.
9. Conclusions
Based on the intended use, technological characteristics, safety testing, performance testing, and clinical study results included in this submission, ev3 considers the proposed TurboHawk Peripheral Plaque Excision System to be substantially equivalent to the currently marketed TurboHawk Peripheral Plaque Excision System (K093301).
4
Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three tail feathers, representing the three levels of government: federal, state, and local. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room ~WO66-G609 Silver Spring, MD 20993-0002
OCT 2 7 2011
ev3, Inc. c/o Ms. Brenda Johnson Principal Regulatory Affairs Specialist 3033 Campus Drive Plymouth, MN 55441
Re: K11723
Trade/Device Name: TurboHawk Peripheral Plaque Excision System Regulation Number: 21 CFR 870.4875 Regulation Name: Intraluminal Artery Stripper Regulatory Class: Class II Product Code: MCW Dated: October 7, 2011 Received: October 11, 2011
Dear Ms. Johnson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. However, we remind you that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your davine (1 hr) found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal-Register. - - DV may
5
Page 2 - Ms. Brenda Johnson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Bram Zuckerman, M.D. Director Division of Cardiovascular Devices
Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1 -
Indications for Use Statement
510(k) Number (if known): K111723
Device Name: TurboHawk® Peripheral Plaque Excision System
Indications for Use:
The TurboHawk® Peripheral Plaque Excision System is intended for use in atherectomy of the peripheral vasculature. The TurboHawk is indicated for use in conjunction with the SpiderFX® Embolic Protection Device in the treatment of severely calcified lesions. The TurboHawk is NOT intended for use in coronary, carotid, iliac or renal vasculature.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Cardiovascular Devices | |
| 510(k) Number | K111723 |